Glucocorticoids Combined With Concurrent Chemoradiotherapy for Unresectable Thymoma
This study aims to assess the efficacy of methylprednisolone combined with concurrent chemoradiotherapy in treating unresectable or recurrent thymoma.
Thymoma
RADIATION: Radiotherapy|DRUG: Concurrent chemotherapy|DRUG: Methylprednisolone
Objective response rate, The percentage of patients who achieve complete remission or partial remission after chemoradiotherapy, 1-2 months after chemoradiotherapy
Progression-free survival, From the start date of initial treatment to progression, death or last follow-up, 2-year|Overall survival, From the start date of initial treatment to death or to last follow-up., 2-year|Toxicities using the CTCAE 5.0, Toxicities were evaluated using the CTCAE 5.0, 1 year after treatment|Quality of life scores, Quality of life assessed by QLQ-C30, 1 year after treatment
This study aims to assess the efficacy of methylprednisolone combined with concurrent chemoradiotherapy in treating unresectable or recurrent thymoma. Patients will receive hypofractionated radiotherapy with concurrent chemotherapy.

Methylprednisolone will be administered daily during radiotherapy at a dose of 2 mg/kg.